Calendario›INCY›INCA00186
INCA00186
Study of INCA 0186 in Subjects With Advanced Solid Tumors
Ensayo de INCYTE CORP en Advanced Solid Tumors · Squamous Cell Carcinoma of the Head and Neck (SCCHN) · Gastrointestinal (GI) Malignancies (del registro, en inglés).
Más ensayos de: Tumor sólido avanzado.
- Fase
- Fase 1
- Estado
- Interrumpido
- Participantes
- 57
- Centros
- 32
- Fin del objetivo primario
- sep 2024
Qué significa cada fase y cada estado.
Estudio de intervención, no aleatorizado, abierto. Comenzó en oct 2021.
Este ensayo se detuvo. Motivo declarado por el promotor (del registro, en inglés): «This was a strategic business decision. There were no safety concerns contributing to this decision.».
Qué mide
Evaluation of the safety and tolerability of INCA00186 as monotherapy and in combination with retifanlimab and/or INCB106385 as measured by the number of participants with adverse eventsductions and withdrawal of treatment due to AEs (90 days after study completion totaling up to 27 months) (del registro, en inglés)
Cómo lo describe el promotor
En el documentoEn inglés, del registroThis is an open-label, nonrandomized, multicenter, dose escalation, and dose expansion first-in human (FIH) Phase 1 study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of INCA00186 when given alone or in combination with INCB106385 and/or retifanlimab in participants with specific advanced solid tumors; squamous cell carcinoma of the head and neck (SCCHN) and specified gastrointestinal (GI) malignancies have been selected as indications of interest for this study. Participants with CD8 T-cell-positive tumors will be selected as these tumors are more likely to respond to immunotherapy.
Más ensayos de INCY
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| tafasitamab · InMIND | Fase 3 | En marcha, sin reclutar | feb 2024 (real) |
| Tafasitamab · MINDway | Fase 1/2 | En marcha, sin reclutar | jul 2024 (real) |
| Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND) | no aplica | Reclutando pacientes | jun 2025 (prevista, ya pasada: sin actualizar en el registro) |
| tafasitamab · J-MIND | Fase 1/2 | En marcha, sin reclutar | jul 2025 (real) |
| INCA034176 | Fase 3 | En marcha, sin reclutar | ago 2025 (real) |
| Povorcitinib | Fase 3 | En marcha, sin reclutar | feb 2026 (real) |
Todos los de INCY, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT04989387), actualizada en ago 2025.